Dare Bioscience gets FDA clearance for HPV treatment phase 2 trial Feb 23, 2026 08:01AM
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer Feb 23, 2026 08:00AM
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women Feb 11, 2026 08:00AM
Daré Bioscience launches sildenafil cream for women's arousal Dec 10, 2025 08:01AM
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facil Dec 10, 2025 08:00AM
View Older Stories

Dec 1, 2025 08:03AM Dare Bioscience regains rights to contraceptive drug from Bayer
Dec 1, 2025 08:00AM Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Nov 24, 2025 08:01AM Dare Bioscience receives $3.6 million Gates Foundation grant payment
Nov 24, 2025 08:00AM Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Nov 13, 2025 04:01PM Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 11, 2025 08:00AM Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women
Nov 6, 2025 08:00AM Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Nov 3, 2025 08:00AM Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Oct 6, 2025 08:03AM Dare Bioscience receives $4 million grant installment for drug delivery
Oct 6, 2025 08:00AM Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Bro
Sep 24, 2025 08:00AM Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Aug 14, 2025 04:01PM Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 7, 2025 08:00AM Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
Jul 29, 2025 08:00AM Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Jul 21, 2025 01:47PM UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Jul 21, 2025 08:00AM Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Jul 14, 2025 08:03AM Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
Jul 14, 2025 08:00AM Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Jul 11, 2025 08:00AM Daré Bioscience receives $6 million grant installment for contraception device
Jul 11, 2025 08:00AM Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application P
Jun 12, 2025 05:00PM Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Jun 4, 2025 08:01AM Dare Bioscience (DARE) and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Jun 4, 2025 08:00AM Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
May 13, 2025 04:01PM Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
May 6, 2025 08:00AM Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
Apr 23, 2025 08:00AM Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation
Apr 7, 2025 08:00AM Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available v
Mar 31, 2025 04:01PM Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Mar 24, 2025 08:00AM Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Feb 20, 2025 08:04AM Daré Bioscience (DARE) and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Feb 20, 2025 08:00AM Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Feb 6, 2025 08:02AM Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Feb 6, 2025 08:00AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Jan 9, 2025 08:00AM Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 16, 2024 08:04AM Dare Bioscience (DARE) Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder
Dec 16, 2024 08:00AM Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Dec 10, 2024 08:00AM Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cr
Dec 4, 2024 08:04AM Dare Bioscience (DARE) Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dec 4, 2024 08:00AM Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Nov 14, 2024 04:01PM Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Nov 13, 2024 08:07AM Dare Bioscience (DARE) Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene Pivotal Study Clinical Trial Sites
Nov 13, 2024 08:00AM Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Nov 7, 2024 08:00AM Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
Oct 23, 2024 12:34PM Dare Bioscience (DARE) Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Oct 23, 2024 12:30PM Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Oct 21, 2024 08:05AM Dare Bioscience (DARE) Announces $15M Common Stock Purchase Agreement with Lincoln Park Capital Fund
Oct 21, 2024 08:05AM Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Aug 26, 2024 08:03AM Dare Bioscience (DARE) Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 26, 2024 08:00AM Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 13, 2024 08:19AM Dare Bioscience (DARE) Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
View Older Stories